Morepen Laboratories Limited · NSE:MOREPENLAB

Morepen Laboratories — Q1 FY2023 Earnings Presentation

29 slides from Morepen Laboratories's earnings presentation, Jul 29, 2022

  1. Slide 1: Investors Presentation cover letter to stock exchanges

    ...·* *.* . • • .,-..-9E,1 1 /lO~EPEH Date: 29/07/2022 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Floor 25, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288 Subject: Investor

  2. Slide 2: Q1'FY23 Earnings Presentation - July 2022

    MOREPEN LABORATORIES LIMITED Q1'FY23 earnings Presentation - jul 2022

  3. Slide 3: Disclaimer/ Confidentiality

    Disclaimer/ Confidentiality This presentation has been prepared by Morepen Laboratories Limited (“Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied

  4. Slide 4: Quarterly Highlights

    CONSOLIDATED QUARTERLY HIGHLIGHTS DEBT FREE COMPANY • Business is consolidating after Covid pandemic disturbance • The company had long standing liability of and expected to stabilise over next 2-3 quarters. 114.65 cr. as outstanding preference capital issued to the Banks/FI's in the • Against peak

  5. Slide 5: Consolidated Quarterly Performance

    CONSOLIDATED quarterly performance

  6. Slide 6: Revenue Growth

    CONSOLIDATED REVENUE GROWTH 26% CAGR Rs. in crores 2,000 ^30% 14% CAGR 1557 1,500 400 1200 388 388.31 1,000 300 863 772 303 up 50% from 259 pre-covid level 500 200 203 100 0 FY'19 FY'20 FY'21 FY'22 0 Q1'FY20 Q1'FY21 Q1'FY22 Q1'FY23 Annual performance Q1'FY23 performance JlOREPEN

  7. Slide 7: Business Segments

    CONSOLIDATED BUSINESS SEGMENTS API BUSINESS MEDICAL DEVICES FORMULATIONS OTC (SUBSIDIARY)

  8. Slide 8: Segments Wise Performance

    CONSOLIDATED SEGMENTS WISE PERFORMANCE API DIAGNOSTICS FORMULATIONS DR.MOREPEN -OTC -20% -42% ^13% ^22% 200 150 50 30 189.97 150 134.46 28.85 40 44.91 151.29 100 39.90 20 23.65 100 30 50 77.71 20 50 10 10 0 0 Q1'FY22 Q1'FY23 Q1'FY22 Q1'FY23 0 0 Q1'FY22 Q1'FY23 Q1'FY22 Q1'FY23 NOTE: comparison for th

  9. Slide 9: Segment Wise Breakup

    STANDALONE SEGMENT WISE BREAKUP Formulations share q1 FY'22 q1'FY23 16.4% API 3.10% f 52.1% 55.2% API 55.2% Diagnostic Devices 28.4% Diagnostics 8.50% 36.9% 28.4% revenue split Q1'FY'23 formulations 5.40% f 11.0% 16.4%

  10. Slide 10: API Business

    API BUSINESS leadership through quality

  11. Slide 11: API Revenue

    api business API REVENUE 28% CAGR Rs. in crores 1,000 ^26% 858 CAGR 10% 750 200 683 189.97 500 150 162.06 up 35% from 151.28 474 413 pre-covid level 100 112.42 250 50 0 FY'19 FY'20 FY'21 FY'22 0 Q1'FY20 Q1'FY21 Q1'FY22 Q1'FY23 Annual performance Q1'FY23 performance

  12. Slide 12: Key API Products

    api business KEY API PRODUCTS LORATADINE MONTELUKAST -23% -32% ATORVASTATIN NEW MOLECULES ^1% ^5% J\\OREPEN

  13. Slide 13: POC Medical Devices

    ---- --- I I I I I I I I I POC MEDICAL DEVICES market leadership < ) r ) ., \

  14. Slide 14: POC Revenue

    POC medical devices POC REVENUE 44% CAGR Rs. in crores 500 ^46% 400 CAGR 19% 419 150 300 134.46 287 100 200 168 77.71 140 up 94% from 100 50 pre-covid level 46.56 40.03 0 FY'19 FY'20 FY'21 FY'22 0 Q1'FY20 Q1'FY21 Q1'FY22 Q1'FY23 Annual performance Q1'FY23 performance JlOREPEN

  15. Slide 15: Gluco Meter Revenue

    POC medical devices GLUCO METER REVENUE 44% CAGR Rs. in crores 300 ^55% 279 CAGR 25% 200 100 180 75 84.47 100 120 63.41 93 50 up 93% from pre-covid level 0 25 32.78 FY'19 FY'20 FY'21 FY'22 25.44 0 Annual performance Q1'FY20 Q1'FY21 Q1'FY22 Q1'FY23 Q1'FY23 performance

  16. Slide 16: Gluco Meter Installed

    POC medical devices GLUCO METER INSTALLED 41% CAGR 2.5 2 ^28% 2.167 ^16% -21% 1.5 1.692 7.91 MILLION 976 MILLION 1 meters installed strips sold so far 0.979 0.774 0.5 q1'Fy23 0.71 MILLION q1'Fy23 68 MILLION 0 FY'19 FY'20 FY'21 FY'22 million meter installed

  17. Slide 17: BP Monitor Revenue

    POC medical devices BP MONITOR REVENUE 47% CAGR Rs. in crores 100 ^33% 75 84 CAGR 40% 25 63 50 20 20.58 15 25 29 27 10 12.83 175% growth from 5 7.33 pre-covid level 0 FY'19 FY'20 FY'21 FY'22 4.67 0 Q1'FY20 Q1'FY21 Q1'FY22 Q1'FY23 Annual performance Q1'FY23 performance

  18. Slide 18: Other Products

    POC medical devices OTHER PRODUCTS 40% CAGR Rs. in crores 60 ^27% 56 40 44 30 29.40 20 20 20 20 10 13.79 0 FY'19 FY'20 FY'21 FY'22 2.58 1.46 0 Q1'FY20 Q1'FY21 Q1'FY22 Q1'FY23 Annual performance Q1'FY23 performance Q1'FY22 revenues include sales of Covid products like thermometers, oxygen concentrato

  19. Slide 19: Formulations

    FORMULATIONS brandeD formulations in india

  20. Slide 20: Formulations Revenue

    FORMULATIONS FORMULATIONS REVENUE 3% CAGR Rs. in crores 200 ^29% 150 169 CAGR 9.5% 153 50 138 131 39.90 100 40 44.91 up 31% from 39.89 pre-covid level 30 34.25 30.65 50 20 10 0 FY'19 FY'20 FY'21 FY'22 0 Q1'FY21 Q1'FY21 Q1'FY22 Q1'FY23 Annual performance Q1'FY23 performance JlOREPEN

  21. Slide 21: Growth Drivers

    FORMULATIONS GROWTH DRIVERS ^4% ^37% antibiotics vitamins ^4% ^26% gastro others J\\OREPEN

  22. Slide 22: OTC & Nutrition

    Dr. Morepen® OTC & NUTRITION

  23. Slide 23: Gross Revenue

    GROSS REVENUE 20% CAGR Rs. in crores 125 ^23% 100 106 CAGR 27 % 75 86 30 65 28.85 50 55 20 23.65 21.69 up 104% from 25 pre-covid level 14.16 10 0 FY'19 FY'20 FY'21 FY'22 0 Annual performance Q1'FY20 Q1'FY21 Q1'FY22 Q1'FY23 Q1'FY23 performance JlOREPEN

  24. Slide 24: Growth Drivers

    GROWTH DRIVERS ^10% ^148% OTC products* grooming -18% 145% general health 0nline Sales Excluding covid range*

  25. Slide 25: Brand Portfolio

    BRAND PORTFOLIO an established national household brand with extensive reach and trust 25% CAGR Rs. in crores ^36% 750 685 CAGR 23% 500 504 200 OTC Rx 195.85 15.4% 371 23.4% 347 150 165.60 250 up 86% from 100 pre-covid level 102.07 88.84 0 50 FY'19 FY'20 FY'21 FY'22 Devices 0 Annual performance 61.2

  26. Slide 26: R&D Spend

    consolidated R&D SPEND increasing investment in R&D Rs. in crores Devices 12.5% ^ 70% 3 API 48.1% 2.76 2 ANDA 39.4% 1.62 1 0 segment wise spend Q1'FY22 Q1'FY23 Q1'FY23 SPEND *Includes R&D/ARD/QC team

  27. Slide 27: Financial Highlights & Ratios

    FINANCIAL highlights & ratios

  28. Slide 28: Revenue Highlights

    CONSOLIDATED REVENUE HIGHLIGHTS net revenue EBIDTA PROFIT BEFORE TAX PROFIT AFTER TAX -22% -66% - 78% - 82% 50 40 400 40 388.31 40 45.43 38.53 300 30 30 303.31 30 30.47 200 20 20 20 100 10 15.46 10 10 8.31 5.63 0 0 0 0 Q1'FY22 Q1'FY23 Q1'FY22 Q1'FY23 Q1'FY22 Q1'FY23 Q1'FY22 Q1'FY23 NOTE: muted deman

  29. Slide 29: Thank you

    f' Thank you love heals

Morepen Laboratories — Q1 FY2023 Earnings Presentation on 6ix